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Abstract
The eruption of Kaposi sarcoma (KS) and aggressive non-Hodgkin lymphoma (NHL) in young homosexual men in
1981 in the West heralded the onset of the human immunodeficiency virus (HIV) infection epidemic, which
remains one of the biggest challenges to global public health and science ever. Because KS and NHL were
increased >10,000 and 50-600 times, respectively, with HIV, they were designated AIDS defining cancers (ADC).
Cervical cancer (CC), increased 5-10 times was also designated as an ADC. A few other cancers are elevated with
HIV, including Hodgkin lymphoma (10 times), anal cancer (15-30 times), and lung cancer (4 times) are designated
as non-AIDS defining cancers (NADCs). Since 1996 when combination antiretroviral therapy (cART) became widely
available in the West, dramatic decreases in HIV mortality have been observed and substantial decrease in the
incidence of ADCs. Coincidentally, the burden of NADCs has increased as people with HIV age with chronic HIV
infection. The impact of HIV infection on cancer in sub-Saharan Africa, where two thirds of the epidemic is
concentrated, remains poorly understood. The few studies conducted indicate that risks for ADCs are also
increased, but quantitatively less so than in the West. The risks for many cancers with established viral associations,
including liver and nasopharynx, which are found in Africa, do not appear to be increased. These data are limited
because of competing mortality, and cancer is under diagnosed, pathological confirmation is rare, and cancer
registration not widely practiced. The expansion of access to life-extending cART in sub-Saharan Africa, through
programs such as the Global Fund for AIDS, Malaria, and Tuberculosis and the US President’s Emergency Program
for AIDS Relief (PEPFAR), is leading to dramatic lengthening of life of HIV patients, which will likely influence the
spectrum and burden of cancer in patients with HIV. In this paper, we review current literature and explore merits
for integrating cancer research in established HIV programs to obtain timely data about the incidence and burden
of cancer in HIV-infected persons in Africa.
Introduction
The global cancer burden has been increasing rapidly
over the past 30 years [1], both in developed and devel-
oping countries [2]. The number of cases almost
doubled from 7.6 million in 2002 to 12.7 million in
2008 [3], and are projected to continue increasing at
70% per year over the next 20 years [4]. The emergence
and alarming spread, of the human immunodeficiency
virus (HIV) epidemic has contributed to these increases.
Heralded by eruption of Kaposi sarcoma (KS) [5,6] and
aggressive non-Hodgkin lymphoma (NHL), including
Burkitt lymphoma (BL) [7,8] in homosexual men in
New York in 1981, the HIV epidemic has impacted the
burden and trend of cancer in different countries.
Abrupt increases in the number of KS cases in countries
in sub-Saharan Africa, where KS was endemic [9,10],
and in different countries in Europe [11], where KS was
rare, signaled the pandemic nature of HIV and the gen-
eral impact of the epidemic on cancer [12-14]. KS and
aggressive NHLs, because of their dramatically elevated
risk (100,000 and 282, respectively, in the U.S. [15])
with HIV and cervical cancer (CC) with less dramatic
increase (10 times), were categorized as AIDS defining
cancers (ADCs) to facilitate AIDS surveillance. Only a
few other cancers were noted to be modestly increased
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cancers (NADCs) [16]. While ADCs contributed the
majority of cancer early in the AIDS epidemic, NADCs
have assumed greater importance as survival has length-
ened and patients are aging with HIV. Cancer now is
estimated to contribute up to one third of deaths in
patients with HIV in developed countries [17,18].
Although 70% of the global HIV/AIDS epidemic is
concentrated in sub-Saharan Africa [19,20], the impact
of HIV on cancer in this region is incompletely
described. The impact of HIV on ADCs in Africa is
similar, but less strong, than in the West [21,22]. Sparse
data preclude detailed comparisons of pattern of
NADCs, but dramatic increase in squamous cell carci-
noma of the conjunctiva (SCCC) in many countries in
Africa suggest the patterns differ from those observed in
the West [21,22]. Behavioral and environmental risk fac-
tors account for the bulk of cancer in developed coun-
tries [23]. Conversely, infections account for
proportionately more cancers in sub-Saharan Africa
[24]. Thus, the impact of HIV on cancer in Africa might
be expected to be different. In this paper, we summarize
the impact of HIV on selected cancers in Africa, based
on a panel discussion at the 12
th International Confer-
ence of the Institute of Human Virology at Tropea,
Italy, in 2010. We summarize the consensus that colla-
boration with infectious disease HIV programs in sub-
Saharan Africa may provide practical opportunities for
research, treatment and prevention about cancer in HIV
infected populations.
HIV and cancer in the West
T h eb u l ko fo u rk n o w l e d g ea b o u tH I Va n dc a n c e r
comes from studies conducted in the West (2448 of
2587 case-referent studies [21]), although this region is
home to about 8% of the HIV epidemic [19,22]. KS,
high-grade B-cell NHL, and cervical cancer (CC) were
classified as ADCs based on data from this region
[20,25], and the studies have shown that risk of KS and
NHL, but not CC, increase with level and duration of
immunosuppression [15,26,27].
KS was rare in the United States before the AIDS epi-
demic. Among white men in San Francisco, an early epi-
center of the AIDS epidemic, incidence of KS rose
steeply from 0.5 per 100,000 people/year in 1973 to a
peak of 33.3 in 1991 [28], but mirroring trends in HIV/
AIDS, the incidence fell to 2.8 in 1998. The risk for KS
among persons with AIDS in the United States as com-
pared with the general population was 22,100 during
1990-95 and 3,640 during 1996-2002 [29]. HIV/AIDS-
related KS was estimated to account for about 81.6% of
all KS cases in the U.S. during 1980-2007 [30]. The con-
tribution of AIDS-related KS as a percentage of total KS
burden in the United States peaked at 90.5% during
1990-95 and declined to 70.5% during 2001-07 [30].
These changes are related to use of combination anti-
retroviral therapy (cART).
In contrast to KS, NHL was relatively common in the
general population in the U.S. and the incidence was ris-
ing before the arrival of the HIV epidemic [28]. Impress-
ive increases were noted for aggressive NHLs, including
diffuse large B-cell lymphoma (DLBCL), BL, and CNS
lymphoma[31]. For example, NHL rates among white
men in San Francisco rose from 10.7 in 1973 to peak at
31.4 in 1995 then declined to 21.6 in 1998, but the inci-
dence rates increased more steeply for DLBCL, BL, and
CNS lymphoma [28]. The risk for NHL among persons
with AIDS in the United States as compared with the
general population was 53.2 during 1990-95 and 22.6
during 1996-2002 [29]. The lifetime cumulative risk of
NHL was about 10% [32,33]. The proportional contribu-
tion of AIDS-related NHL subtypes to all NHL peaked
in the early 1990s (10.2% for DLBCL, 27.8% for BL, and
48.3% for CNS lymphoma) then declined to 4.7%, 21.5%,
and 12.9% for DLBCL, BL, respectively, during 2001-07
[30].
The risk pattern for CC contrasts that of KS and
NHL. Modest risk elevation of 4.2 times during 1990-95
and 5.3 during 1996-2002 was noted [29]. The propor-
tional contribution of AIDS-related CC in the United
States during 1980-2007 was low at only 0.4% of all
cases [30], although it has increased from 0.1% during
1980-89 to 0.71% during 2001-07 [30]. In contrast to KS
and NHL, CC is not associated with level and duration
of immunosuppression [15,26,27]. Possibly, screening for
CC has capped its incidence in the West.
The introduction of cART in the West in 1996 [34,35]
and its fast scale-up resulted in rapid and sustained
reductions in mortality from AIDS and in the incidence
of KS and NHL, but not CC [16,36,37]. The substantial
reduction in risk for KS and aggressive NHLs following
widespread introduction of cART is consistent with the
hypothesis that HIV influences risk for cancers via cellu-
lar immunosuppression and impairment of oncovirus
immunosurveillance [16].
The incidences of several other cancers, including
lung, anus, liver, and Hodgkin lymphoma are increased
with HIV/AIDS. These cancers are currently considered
NADCs, and the reasons for the increased incidences
are varied. For example, lung cancer incidence has con-
sistently been shown to be increased 3-4 times higher in
persons with HIV/AIDS [30,38,39]. A high prevalence of
cigarette smoking in persons with HIV/AIDS compared
to the general population is generally believed to explain
this increase, although, other cofactors, including altered
pathophysiology of the lung with HIV infection, may
contribute [40]. For anal cancer, co-infection with HPV
i st h o u g h tt ob eak e yf a c t o r[41], while uncontrolled
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increase[26].
Intriguingly, breast and prostate cancer incidences
rates appear decreased with immunosuppression [15,42].
The reasons for this pattern are not well understood,
but they may include direct and/or indirect effects of
HIV infection on breast cells [43]. For breast cancer,
H e s s o la n dc o l l e a g u e s[ 4 4 ]p o s t u l a t e dt h a tC X C R 4 -
expresing HIV virions reduce breast cancer risk by indu-
cing apoptosis of neoplastic breast cells via interaction
with the CXCR4 receptor, which is expressed on some
breast cancer cells. Conversely, the prostate cancer defi-
cit in people with HIV/AIDs seems to be related to
early case detection in this group because greater access
to prostate cancer screening using prostate specific anti-
gen [42].
The incidence rates of most common epithelial can-
cers, such as colon cancer, are not increased [15,38].
Absence of a generalized cancer epidemic in the set-
ting of HIV has cast doubt on the hypothesis that
immunological surveillance for tumor plays a major
role in keeping progression to cancer in check. How-
ever, long-term effects of HIV on cancer will become
clearer as we study the spectrum of NADCs in aging
HIV infected population on long-term treatment with
cART [39,45].
HIV and cancer in sub-Saharan Africa
Although the region is home to about 70% of the AIDS
pandemic, only about 139 (5%) studies have been con-
ducted to examine the impact of HIV and cancer in
sub-Saharan Africa [21]. One of these studies used HIV/
AIDS-cancer record linkage methods, in Uganda [46],
which demonstrated the feasibility of using this
approach to study cancer in poor countries. About
681,000 people are diagnosed with cancer in sub-
Saharan Africa annually [4]. Given the size of the HIV
epidemic in the region, even a small impact of HIV on
cancer can result in substantial increase in cancer bur-
den, especially as longevity increases due to widespread
access to cART. KS and squamous cell carcinoma of the
conjunctiva (SCCC) exhibit the strongest quantitative
association with HIV/AIDS in sub-Saharan Africa
[47-50]. The impact of HIV on cancers with established
virus-associations, including BL, liver cancer, and naso-
pharyngeal carcinoma, is less clear [51]. The impact of
HIV on ADC is summarized in Table 1 and reviewed
below.
Table 1 Association between AIDS-defining cancers with HIV in children and adults in studies conducted in sub-
Saharan Africa
Cancer Country Subjects OR (95%CI) Reference
Kaposi sarcoma Uganda Children 94.9 (28.5-315) Newton et al., 2001[47]
Malawi Children 93.5 (26.9-324) Newton et al., 1995[67]
Uganda Adults 6.4 (4.8-8.4) Mbulaiteye et al., 2006 ± [46]
Rwanda Adults 35 (8.2-207) Newton et al., 1995[72]
South Africa Adults 22 (12.5-39) Sitas et al., 2000[73]
South Africa Adults 47.1 (31.9-69.8) Stein et al., 2000[74]
Non-Hodgkin lymphoma
Burkitt lymphoma Uganda Children 7.5 (2.8-20.1) Newton et al., 2001[47]
Uganda Children 2.2 (0.9-5.1) Parkin et al., 2000[51]
Malawi Children 12.4 (1.3-116) Mutalima et al., 2008[68]
Malawi Children 2.2 (0.8-6.4) Mutalima et al., 2010[67]
South Africa Children 46.2 (16.4-130) Stefan et al., 2011[69]
Non-Burkitt NHL Malawi Children 4.4 (1.1-17.9) Mutalima et al., 2010[67]
South Africa Children 5.0 (0.9-27.0) Stefan et al., 2011[69]
Uganda Adults 6.2 (1.9-20) Newton et al., 2001[47]
Uganda Adults 6.7 (1.8-17) Mbulaiteye et al., 2006 ± [46]
South Africa Adults 5.0 (2.7-9.5) Sitas et al., 2000[73]
South Africa Adults 5.9 (4.3-8.1) Stein et al., 2000[74]
Cervical cancer Uganda Adults 1.6 (0.7-3.6) Newton et al., 2001[47]
Uganda Adults 2.4 (1.1-4.4) Mbulaiteye et al., 2006 ± [46]
South Africa Adults 1.6 (1.1-2.3) Sitas et al., 2000[73]
South Africa Adults 1.6 (1.3-2.0) Stein et al., 2008[74]
± Results based on record-linkage study; estimates represent standardized incidence ratios comparing risk of cancer in persons with HIV to the general
population where cancers arose. OR, odds ratio; 95%CI, 95% confidence interval.
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Kaposi sarcoma
KS was endemic in East and Central Africa before the
AIDS epidemic accounting for 5-18% of cancers [9,10].
During the AIDS epidemic, KS has become the most
common cancer (Table 1) [52-54]. In Uganda, the
annual age-standardized incidence rate per 100,000 men
rose 12 times from 3.2 in 1960-66 to 39.3 in 1995-97
and from 0.1 to 21.8 per 100,000 women during the
same periods (Figure 1) [52]. The proportion of KS in
childhood cancers increased from 2% in the 1960s to
33% in the 1990s. The risk for KS with HIV/AIDS was
elevated 6 times relative to KS rates in the contempora-
neous general population in the Uganda HIV/AIDS
Cancer match Study (Figure 2, SIR using contempora-
neous, AIDS era, comparison data) [46]. The relatively
modest increase in KS incidence in Africa compared to
that observed in the West may be due to high back-
ground rates of KS and of HIV in the general popula-
tion. In support for this explanation, the risk of KS in
men, women, and children was much higher when the
general population in the pre-AIDS KS years of 1960-
1971 were used (Figure 2, SIR using pre-AIDS KS popu-
lation incidence rates) as comparator. Another notable
impact of HIV on KS was the loss of the large gender
disparity in male/female incidence ratio from 20:1 in
endemic KS to 2:1 in AIDS-related KS. The KS gender
disparity (observed in classical KS as well) is not
explained by differences in KSHV seroprevalence in
men and women, which differ only by 20-50% [55]. Loss
of gender disparity in the setting of immunosuppression
suggests that immunocompetent women may be pro-
tected by gender-specific immunobiological factors [56],
but the nature of these factors is unknown. A hypothesis
that women might be protected by female hormones
was advanced, but it not supported by reports that KS
occurs in pregnant women[9,57] and laboratory studies
have failed to find sex-hormone receptors on KS tissues
[58]. KS risk is linked to environmental factors [59,60],
KSHV viremia [61,62], expression of HIV proteins [63],
immune reconstitution syndrome [64] and severe immu-
nosuppression, some of which may contribute to gender
disparity. Recently, Ruocco et al., [65] has advanced the
quinine or “oncodrug” hypothesis for KS in Africa, but
this remains to be tested, and it would not explain the
gender disparity. AIDS-related KS is a unique model of
the relationship between viral infection, immunity,
environmental, and genetic factors in viral cancers. Stu-
dies of KS patterns during the rollout of cART pro-
grams to document changes in the incidence and male/
female ratio and the association, if any, with antimalarial
use, may provide valuable insights into the biology of
KS in Africa.
Non-Hodgkin lymphoma
In contrast to KS, the risk for NHL in the general popu-
lation in sub-Saharan Africa is relatively low[66], except
for childhood BL, which is endemic in some countries
where it may accounts up to 50-75% of childhood can-
cers. Whether HIV has increased the risk of NHL risk
in sub-Saharan Africa [67-69], especially of BL in parti-
cular, is unclear. The cumulative lifetime risk of NHL
for AIDS patients in sub-Saharan Africa is about 3%,
which is lower than about 10% observed in more devel-
oped countries at the onset of the epidemic [32]. In his
autopsy study of 247 adult (>14 years) patients dying
from AIDS-related conditions during 1991-1992, Lucas
et al., [70] found NHL in only 2.8% of HIV-positive
decedents in Côte d’Ivoire. He estimated that the crude
incidence of NHL was 84/100,000 per year among HIV-
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Figure 1 Age-standardized incidence rates for AIDS-defining
cancers (ADC) in Kyadondo County, Uganda for time-periods
before and after the onset of the AIDS epidemic (early 1980s).
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p r e - A I D Si n c i d e n c eo fN H L .N o n eo f7 8a u t o p s i e d
HIV-positive children (median age = 17 months) had
NHL. Case series data of 26 adults (aged >16 years)
with BL in Kenya during 1992-96 were compatible with
an increase three times that expected from previous
estimates [71]. The median age of HIV-positive patients
with BL was 35 years compared with 16-25 years for
those who were HIV-negative, and the HIV positive
cases presented with lymph node involvement, indicat-
ing a departure, most likely as a result of the HIV epi-
demic, from the presentation typically seen in endemic
BL. Recent reports from the Kampala Cancer Registry in
Uganda have noted that NHL incidence rates increased
three times from 2.3 per 100,000 persons in 1961 to 6.6
in 1997 (Figure 1) [52]. This increase was mostly due to
pediatric BL (from 0.9 to 3.8 over the time period) and
to DLBCL in young adults, which is compatible with an
increase due to AIDS, but less so than observed among
HIV-positive adults in industrialised countries.
The risk of NHL with HIV has been quantified in a
few studies (Table 1). In Rwanda, Newton et al. [72]
found an odds ratio (OR) for HIV of 12.6 (95%CI, 2.2-
54.4), based on 19 clinically and histologically diagnosed
NHL cases. In South Africa, Sitas et al. [73] found an
OR for HIV of 5.0 (95%CI, 2.7-9.5), based on 105 histo-
logically confirmed adult NHL cases compared with 844
hospitalized control subjects who had cancers unrelated
to HIV (in adult men) or vascular disease (in adult
women), enrolled at a tertiary hospital. These results
have been confirmed in more recent analyses including
larger numbers from South Africa [74]. The SIR for
NHL was elevated 6.7 (95%CI, 1.8-17) times than in the
general population in the Uganda HIV/AIDS-cancer
match study [46]. However, the finding of marginal or
null association with HIV has been reported at least one
study in Uganda: OR of 2.2 (95%CI, 0.9-5.1), based on
38 histologically confirmed cases [51].
The reasons for the comparatively lower risk of NHL
in sub-Saharan Africa relative to rates observed in the
West may be artifactual due to under-diagnosis or may
be due to competing mortality or environmental/genetic
factors. Survival with HIV may be too short due to com-
peting mortality from common infections, such as
malaria and tuberculosis [75], to permit the significant
development of NHL. This reason was supported by
findings of fewer subjects with severely depressed CD4
+
counts in sub-Saharan Africa than in the West [76].
However, report of a median survival of 10 years from
HIV sero-conversion in a longitudinal data from a rural
cohort in southwest Uganda [77] is comparable to survi-
val observed in western countries before effective antire-
troviral drugs were introduced and the individuals have
had the opportunity to develop NHL. Under-diagnosis,
especially the limited availability of pathological diagno-
sis, may contribute [78]. Might racial factors contribute?
Generally, NHL incidence is lower in African-American
m e na n dw o m e nt h a ni nw h i t em e na n dw o m e n[ 2 8 ] ,
perhaps because of differences in environment, health
care access and/or genetic factors. Possibly, the lower
NHL risk with HIV in sub-Saharan Africa may reflect
part of a general pattern of lower NHL risk in Blacks.
Is it possible that decreased risk of NHL might be due
to prevalent exposure linked to treatment of common
infections in the region? For example, antimalarials,
including chloroquine, are widely used in Africa through
formal prescription as well as self-medication for fever
is prevalent [79]. In this regard, we are intrigued by
recent animal data showing that administration of anti-
malarials to mice transgenic for c-myc inhibits B cell
lymphomagenesis [80]. We are also intrigued by the
widely accepted view that immune activation may con-
tribute to HIV/AIDS-related lymphomagenesis [81]. If
s o ,w ew o u l de x p e c tah i g hi n c i d e n c eo fN H Li ns u b -
Saharan Africa because immune activating infections,
such as malaria, tuberculosis, are common in Africa. We
observe the opposite. Is it possible that treatments for
these conditions, by reducing immune activation, may
coincidentally lower the risk of NHL as well? This
hypothesis is compatible with recently published find-
ings of reduced HIV-induced immune activation in a
Ugandan cohort receiving antitubercular therapy [82].
Clearly, firm conclusion on these issues must await new
data on the impact of HIV on NHL that will emerge
from new studies that are being conducted with
improved diagnostic and data capture methods.
Cervical cancer
Cervical cancer is the most common cancer in women
in most countries in sub-Saharan Africa [47,73], but the
impact of HIV on invasive CC is unclear. Screening pro-
grams for CC in sub-Saharan Africa are not well devel-
oped, so we would not expect to be able to readily
demonstrate HIV-related increase in CC incidence. No
dramatic increase has been noted in registry-based stu-
dies and clinical reports do not suggest a dramatic
increase in number of cases, or drastic change in mean
age incidence or disease stage at diagnosis [83]. The
associations between CC and HIV have been small or
null. For example, in Uganda, Newton et al., [47]
observed an HIV prevalence of 32% in 65 women with
CC attending four large referral hospitals in Kampala
versus 21% observed in 112 controls with non-HIV
related cancers or noncancerous conditions recruited at
the same hospitals (OR, 1.6; 95% CI, 0.7-3.6). Similarly
marginal results have been reported in a study con-
ducted in South Africa, where the prevalence of HIV
among 1323 cases of CC was 12.6% versus 9.0%
observed in a comparison group of women hospitalized
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disease (OR, 1.6; 95% CI, 1.1-2.3) [47,73]. The risk for
CC was 2.4 times (95% CI, 1.1-4.4) in women with HIV/
AIDS in Kampala compared with women in the general
population in the same area in the Uganda HIV/AIDS
cancer match [46]. These results are compatible with a
modest elevation in CC risk with HIV, and the conclu-
sion that the impact of immunosuppression on CC risk
is likely small.
The prevalence of cervical intraepithelial neoplasia
(CIN) or human papilloma virus (HPV) infection is ele-
vated 2-6 times in HIV-positive women than in HIV-
negative women in east [84,85], west [86,87], and south-
ern Africa [88], although not all studies agree [89-91].
In their study of Nairobi prostitutes in 1992, Kreiss et
al., [89] found cervical HPV DNA in 37% of HIV
infected women versus 24% in HIV non-infected women
(OR, 1.7, 95% CI 0.8-3.6). The OR for HPV DNA in
women attending an antenatal clinic in Mwanza in Tan-
zania was 1.02 (95%CI, 0.6-1.6) [90]. The link between
squamous intraepithelial lesions (SIL) and immunity has
not been fullu characterized [92]. The risk of low grade
SIL was 6.1 (95%, CI = 1.2-41.4) times elevated in
w o m e nw i t hC D 4 +c e l lc o u n t<2 0 0 / m m
3 compared to
those with higher counts [92], although these findings
w e r eb a s e do n2 0s u b j e c t sw i t hS I L .I nal a r g e rs t u d y
including 710 HIV positive women in Rwanda, Anastos
et al., [93], found cervical HPV DNA (HPV 16 contribu-
ted 14%) in 67% of the women, of whom 8.8% also had
CIN grade 3. Detection of HPV other than 16 was inver-
sely associated with CD4 counts. Interestingly, a positive
association between malaria infection in the past 6
m o n t h sa n dr i s ko fC I N 3 ,w h i c hh a sn o tb e e nr e p o r t e d
before, was observed. The risk of high grade SIL was 2.4
times higher in HIV positive women with <200 CD4/ml
than HIV positive women with >500 CD4/ml in a study
of 1,010 HIV positive women in South Africa [94]. In
this study, detection of HPV 16 and 66 were inversely
related to CD4 count. Taken together, the modest
increase in CC with HIV is compatible with a small
impact due to HIV, but the relationship with immunity
is observed only with pre-invasive CC lesions.
Despite the small risk increases reported, CC is the
most important cancer in HIV infected populations in
Africa because women account for >50% of HIV epi-
demic. The public health impact of CC could be
addressed by harnessing the historical interest and
increased funding of HIV/AIDS treatment and preven-
tion programs to support new initiatives for CC screen-
ing and treatment [95]. This approach has been
attempted in Zambia with great success [95,96]. The
Zambian model has brought 58,000 women, including
HIV negative women, for CC screening up from 0 less
than 5 years ago by leveraging available, broad-based
capacity-building efforts of vertical HIV/AIDS care and
treatment programs. These modest programs are saving
about one CC death per 46 HIV-positive women
screened, demonstrating potential public health benefit.
The program will yield timely data on HPV infection
and risk for cervical dysplasia among HIV-infected
women in Africa [93], and might make it possible to
examine novel hypotheses, such as the interaction
between malaria and CC [93].
Non-AIDS-defining cancers
Squamous cell carcinoma of the conjunctiva
Squamous cell carcinoma of the conjunctiva (SCCC) is a
rare tumor of the ocular surface, which is linked to ultra-
violet radiation exposure and, based on elevated risk with
HIV [97], appeara to be etiologically linked to immuno-
suppression and/or an underlying, albeit not yet well-
characterized infection. The link with HIV infection was
first reported by Ateenyi-Agaba in 1995 [50] when he
observed that 75% of patients with SCCC at Mulago Hos-
pital in Uganda were HIV-seropositive compared with
only 19% of cases with nonmalignant eye conditions.
This finding was confirmed in other case-control studies
conducted in the tropics and subtropics [97,98], but it
has not been reported in South Africa [74], suggesting
that ultraviolet exposure may be a necessary component
of the HIV impact. The risk of SCCC in Uganda 15
times from before to during AIDS. The incidence rate of
ocular tumors, which are mostly due to SCCC, in Kya-
dondo County rose from 0.2 per 100,000 person-years in
1960-66 to 3.0 in 1995-97. The proportion of SCCC in
eye tumors during the same period increased from
23.5 to 71% in men and 0 to 85% in women [52]. The
dramatic increase in SCCC focused attention on the
role of immunity and infection in SCCC, prompting a
search for infectious etiology, including of mucosal or
genital high-risk and cutaneous HPV [99-103]. de Kon-
ing et al. have summarized the comprehensive litera-
ture on the association between HPV and SCCC [103]
The studies conducted have reported a higher preva-
lence of cutaneous HPV, but not genital HPV types, in
SCCC (OR ranges 8 - infinity) [103]. The frequency or
load of HPV DNA does not appear to vary with histo-
logical grade of tumor [103]. The studies conducted
thus far remain are relatively small, and the positive
results may be biased, while differences in laboratory
methodology for HPV detection is a limitation likely
shared by all the studies. Nonetheless, the consistent
finding of elevated risk of SCCC with HIV supports
the hypothesis that a known or novel HPV or other
infectious agents may be involved in SCCC etiology,
w h i l et h ea b s e n c eo fi m p a c ti nS o u t hA f r i c a ,s u g g e s t s
effects of immunosuppression are expressed on a back-
ground of exposure to ultraviolet radiation.
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Hodgkin lymphoma, although not designated as AIDS
defining, is consistently elevated with HIV in most stu-
dies [15,104]. The risk was elevated in the Uganda HIV/
AIDS cancer match study (OR, 5.7; 95%CI, 1.2-17) and
in a case-control study conducted in South Africa (OR,
1.4; 95%CI, 1.0-2.7). Interestingly, some [105] but not all
studies [106] conducted in the West have reported that
risk for Hodgkin lymphoma with use of cART. Whether
Hodgkin lymphoma risk will further increase as cART
becomes widely available in sub-Saharan Africa will be
clarified by follow-up studies of cohorts on cART in
Africa.
Liver cancer
Hepatocellular carcinoma (HCC) was relatively common
i nm e ni nA f r i c ab e f o r et h eA I D Se p i d e m i c ,i np a r t ,
because of the high prevalence of hepatitis B virus
(HBV) infection and exposure to aflatoxin[66]. There is
no evidence that HCC risk has increased during the
AIDS epidemic, although data for deep seated tumors
in Africa should be considered largely incomplete. The
rates of liver cancer in Uganda, one of the first coun-
tries to be touched by the AIDS epidemic[107], were
stable among men, but they increased by 50% among
women from 1960-80 to 1991-05 [108]. Given the high
prevalence of chronic HBV infection, aflatoxin exposure,
and to a lesser extent hepatitis C infection in sub-
Saharan Africa [109,110], a surge in HCC cases might
have been expected. This reasoning is supported by
recent data suggesting that HIV might be associated
with significant liver fibrosis [111]. However, as liver
cancer has a long induction period, the associations
with HIV might not be expected early in the HIV/AIDS
epidemic, and lower risk might be related to under-
diagnosis, non-pathological confirmation, and short sur-
vival. Continued surveillance of HCC might provide
improved understanding of the impact of HIV in HCC
risk in sub-Saharan Africa.
HIV and cancer in sub-Saharan Africa: caveats and
opportunities
Evaluation of cancer statistics must focus on the quality
of data available to support scientific and public health
initiatives. Although based on the best data currently
available, the impact of HIV on the incidence and bur-
den of cancer is probably underestimated. Only about
one third of people with HIV in sub-Saharan Africa
know about their infection [112] and only about one
third of those who need HIV-specific treatments are
receiving them [46,113]. In addition, cancer registration
is relatively underdeveloped [114]. Although record-link-
age methods, which have been used effectively and effi-
ciently in the West, are feasible in Africa [46], lack of
high-quality computerized medical records [115] pre-
cludes use of some other effective methods.
The study of cancer in HIV persons in Africa is valu-
able for several reasons. First, the large size of the HIV
epidemic underscores its public health significance,
including in its impact on cancer. Two, Africa encom-
passes extraordinary genetic diversity of pathogens and
hosts, which hold promise for unique opportunities to
learn about the biology of infection, immunology and
cancer. Two HIV types are relevant to the epidemic
(HIV-1 and HIV2), but HIV-1 is responsible for 95% of
HIV infections globally. HIV-1 is divisible into ten sub-
types (A-H, J, K) and some circulating recombinant
forms are recognized [116], which have different trans-
mission potentials and pathogenesis and could, plausi-
bly, be associated with differential risk of cancer, and
vary by geography. HIV-2 infection has a restricted dis-
tribution confined to West Africa, where co-distribution
with HIV-1 offers opportunity to investigate HIV-type
specific effects. For example, one small study including
40 women found that HIV-2 was associated with
increased HPV clearance [117] and women infected
with HIV-2 were less likely to develop high-grade SIL
(HR, 0.3; 95%CI, 0.1-0.9) than those infected with HIV-1
[118]. This finding should be interpreted with caution
because the small size of the study, and it was not statis-
tically significant when CD4 counts were taken into
account. HIV-1, subtype C accounts for about half
(48%) of all global HIV-1 infections [116], and is the
major subtype in southern Africa. Subtypes A and D are
predominant in equatorial sub-Saharan Africa, where
they account for 12% and 2%, respectively, of HIV-1
infections. Subtypes B and G account predominate in
the West and the Far East Africa and they account for
11% and 5%, respectively, of HIV-1 infections. Inter-
HIV-1 subtype recombinants are playing an increasingly
important role. They account for 20% of infections
occurring in all regions. There are rare subtypes such as
F, H, J, and K, which together account for <1% of infec-
tions [116]. Most current knowledge about the link
between HIV and cancer risk is based on populations
with subtype B, highlighting our still very limited knowl-
edge of interactions between HIV, host immunogenetics,
and cancer.
Globally coordinated efforts aimed at interrupting the
spread of, and mortality from, HIV/AIDS in sub-
Saharan Africa present opportunities to study cancer in
individuals with HIV/AIDS on the continent [19]. Mil-
lennium Development Goal (MDG) 6, established by the
UN General Assembly Special Session in 2000 to halt
and reverse the spread of HIV-1, malaria, and other dis-
eases, led to the creation of the Global Fund for AIDS,
Tuberculosis, and Malaria and unprecedented opportu-
nities for funding. The US President’s Emergency Plan
for AIDS Relief (PEPFAR) launched shortly thereafter
provided additional funding streams for HIV prevention
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gely ignore cancer [121], have created a funding stream
that has seen access to HAART increase from <1% in
1999 to 35% in 2009 [19] and resulted in dramatic
declines in the rate of new infections, stabilization of the
epidemic, reduction of AIDS-related mortality, and
increase in life expectancy [122]. This funding stream
has strengthened infrastructure for HIV/AIDS disease
surveillance, diagnosis, and data capture and established
large or networked cohorts [115,123]. The resulting
infrastructure and cohorts could be converted to provide
new data on cancer in sub-Saharan Africa. For example,
more than 13,000 PEPFAR clinics provide HIV preven-
tion and treatment to millions of individuals in sub-
Saharan Africa. Similarly, the International Epidemiology
Databases to Evaluate AIDS (IeDEA), a global consor-
tium funded by the National Institutes of Health, has
linked 183 clinics in 17 countries in sub-Saharan Africa
serving 286,793 individuals [124]. These large linked
clinics offer three broad-based opportunities: to define:
a) the spectrum of common and rare cancers in HIV-
infected individuals and to obtain precise estimates of
risk and heterogeneity of risk; b) temporal trends on
common and rare cancers, including before and after
introduction of cART; and c) test specific hypothesis,
such as investigating the risk of KS with immune recon-
stitution syndrome [64,125], the role of antimalarials in
NHL or other cancers, and the role of genetic and/or
viral co-infections in cancer [20], or assess impact of
interventions. We think the opportunities may be best
considered along the lines of a resource-focused and
disease-focused approach, as discussed below.
Resource-focused approach
The resource-focused approach would aim to leverage
large networked or linked clinics [124,126,127] to routi-
nely collect data that can be used for multiple studies
and purposes. In the West, efforts such as the Swiss
Cohort Studies [128] and the U.S. HIV/AIDS Cancer
Match Study [29] provide useful models to consider.
Because cancer is rare even in people with HIV, com-
bining data from different cohorts allows investigators
to address questions pertaining to HIV/AIDS that can-
not be answered in small single institution cohorts. We
are encouraged by establishments of such cohorts in
Africa, prominently including the IeDEA consortium
(http://www.iedea-hiv.org), which was launched with
funding from the National Institutes of Health, to col-
lect, harmonize, and standardize data from the continent
to allow comparative analysis of common and dissimilar
impacts [129]. The African Organization for Research
and Training in Cancer (AORTIC) (http://www.aortic.
org/) has a mission is to promote cancer awareness and
improve cancer diagnosis and treatment in Africa. With
its network across the continent and bi-ennial scientific
meetings, AORTIC provides a resource that could be
leveraged to initiate, implement, and report on Africa-
wide studies of cancer. The recent focus large biomedi-
cal centers, such as the National Cancer Institute at
NIH, by establishing Centers for Global Health[130] is
timely and likely to speed up the conversion of infec-
tious disease-specific programs in developing countries
into programs for study and control of cancer.
Disease-focused approach
In contrast to the resource-focused approach, in the dis-
ease-focused approach, specific hypotheses are raised and
specific studies designed to answer those questions. For
example, the question of the types and risk of NHL is
currently being addressed by a consortium of investiga-
tors focused on lymphomas (http://www.ssalc.org/acsr_-
drupal/). These investigators will bring clarity to the
question of the spectrum of lymphomas diagnosed with
HIV in Africa and their diagnostic support is likely to
spur epidemiological and clinical studies of NHL. We
noted outstanding questions about the etiology of SCCC
[97,99]. Disease-specific hypothesis-driven studies to
investigate the role of immunosuppression, ultraviolet
exposure, pathogens in the pathogenesis of the disease
will bring clarity to our understanding of SCCC. Other
interesting questions that could benefit from a disease-
focused approach include understanding the association
between HIV and lung and breast cancer. The risk for
lung cancer is increased with HIV in the West, but given
the much lower prevalence and intensity of cigarette
smoking in sub-Saharan Africa, studies conducted there
might shed light on the biology of the disease among
non- or low-intensity smokers. The risk of breast cancer
is decreased with HIV in the West [43]. Hessol et al. and
co workers [44] have linked low breast cancer risk with
HIV to infection with CXCR4-using variants of HIV.
They speculated that CXCR4-using variants might reduce
breast cancer risk by binding to apoptosis receptors on
hyperplastic and neoplastic breast duct cells. This
hypothesis brings new perspectives to the question about
the biology for breast cancer with potential for treatment
or intervention using CXCR4-agonists. Data about breast
cancer in sub-Saharan Africa are sparse with some
reporting increased risk [131,132] and others no increase
[46]. Thus, clarifying the epidemiology of breast cancer
in sub-Saharan Africa where CXCR4-using variants are
prevalent may help evaluate the feasibility of testing and
confirming or refuting this hypothesis. Finally, anal can-
cer is increased with HIV in the West [41]. Homosexual
practices are being increasingly acknowledged in Africa,
opening opportunity to investigate the association.
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